Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity

Preparation and stability of lipid-coated nanocapsules of cisplatin: anionic phospholipid specificity

Cisplatin nanocapsules represent a novel lipid formulation of the anti-cancer drug cis-diamminedichloroplatinum(II) (cisplatin), in which nanoprecipitates of cisplatin are coated by a phospholipid bilayer consisting of a 1:1 mixture of zwitterionic phosphatidylcholine (PC) and negatively charged pho...

Full description

Saved in:
Bibliographic Details
Published in:Biochimica et biophysica acta Vol. 1663; no. 1; pp. 135 - 142
Main Authors: Velinova, Maria J, Staffhorst, Rutger W.H.M, Mulder, Willem J.M, Dries, Arno S, Jansen, Bart A.J, de Kruijff, Ben, de Kroon, Anton I.P.M
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 27-05-2004
Subjects:
Animals
Anionic phospholipid
Anions
Antineoplastic Agents - blood
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacokinetics
Antineoplastic Agents - pharmacology
Capsules
Cell Line, Tumor
Cisplatin
Cisplatin - blood
Cisplatin - chemistry
Cisplatin - pharmacokinetics
Cisplatin - pharmacology
Drug Compounding - methods
Drug delivery
Drug Stability
Freezing
Humans
Lipid formulation
Mice
Nanocapsule
Nanotechnology
Phospholipids - chemistry
Stability
Temperature
Water - chemistry
Nanocapsule
Drug delivery
Stability
Lipid formulation
Anionic phospholipid
Cisplatin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cisplatin nanocapsules represent a novel lipid formulation of the anti-cancer drug cis-diamminedichloroplatinum(II) (cisplatin), in which nanoprecipitates of cisplatin are coated by a phospholipid bilayer consisting of a 1:1 mixture of zwitterionic phosphatidylcholine (PC) and negatively charged phosphatidylserine (PS). Cisplatin nanocapsules are characterized by an unprecedented cisplatin-to-lipid ratio and exhibit increased in vitro cytotoxicity compared to the free drug [Nat. Med. 8, (2002) 81]. In the present study, the stability of the cisplatin nanocapsules was optimized by varying the lipid composition of the bilayer coat and monitoring in vitro cytotoxicity and the release of contents during incubations in water and in mouse serum. The release of cisplatin from the PC/PS (1:1) nanocapsules in water increased with increasing temperature with a t 1/2 of 6.5 h at 37 °C. At 4 °C, cisplatin was retained in the nanocapsules for well over 8 days. Replacement of PS by either phosphatidylglycerol or phosphatidic acid revealed that nanocapsules prepared of PS were more stable, which was found to be due to the ability of PS to form a stable cisplatin–PS coordination complex. Mouse serum had a strong destabilizing effect on the cisplatin nanocapsules. The PC/PS formulation lost over 80% of cisplatin within minutes after resuspension in serum. Incorporation of poly(ethylene glycol 2000) (PEG)-derivatized phosphatidylethanolamine and cholesterol in the bilayer coat extended the lifetime of the cisplatin nanocapsules in mouse serum to almost an hour. The results demonstrate that specificity in the interaction of cisplatin with anionic phospholipids is an important criterium for the formation and stability of cisplatin nanocapsules.
ISSN:0005-2736
0006-3002
1879-2642
DOI:10.1016/j.bbamem.2004.03.002